A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum

Key Inclusion Criteria:

1. Signed and dated informed consent
2. Male or female participants aged 18 to 75 years at screening
3. Have an established diagnosis of PXE
4. Fully vaccinated for coronavirus disease 2019 (COVID-19) per current Center for Disease Control and Prevention guidelines

Key Exclusion Criteria:

1. Have a history of bone fracture in the past 6 months
2. Have a history of active metabolic bone disease, excluding osteopenia or osteoporosis without fragility fracture
3. Have a history of calcium pyrophosphate deposit disease
4. Have a history of hypophosphatasia
5. Have a history of untreated hyperparathyroidism
6. Participated in another interventional research study in the past 60 days.
7. Used bisphosphonate in the preceding 12 months or had plans to use bisphosphonate during the study.
8. Received Vitamin B6 supplementation >5 mg/day in the month prior to screening and during the study
9. Initiated or changed dose of Vitamin D in the preceding month prior to screening
10. Have an alkaline phosphatase
11. Have a QTcF interval duration >450 ms at screening
12. Have moderate to severe renal insufficiency
13. Are pregnant or breast-feeding women
14. Are female participants unwilling to use contraceptive methods
15. Have any elective surgery planned during the study period
16. Have any other significant condition (medical, psychiatric, social, or medication) that, in the judgment of the Investigator, would prevent full participation or would be inappropriate for the study